Isabel Piel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Isabel Piel has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Alexander David James
Novartis Pharma AG Basel Switzerland
2 shared publications - Cathy Cantalloube
Sanofi Chilly‐Mazarin France
2 shared publications - Clare Vickers
Neuroscience Discovery, Medicinal Chemistry AbbVie (Deutschland) GmbH & Co. KG Knollstrasse D-67061 Ludwigshafen Germany
2 shared publications - Felix Huth
Novartis Biomedical Research, Basel, Switzerland
2 shared publications - Filip Cuyckens
Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
2 shared publications - Frank Oellien
Neuroscience Discovery, Medicinal Chemistry, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen, Germany
2 shared publications
Latest Publications
- 3 July 2026
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 40 (5) , 327-333
Regulatory Considerations for Combined Drug-Device Studies in Europe: A Case Study Involving Bile Sampling
- 3 July 2026
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 40 (5) , 327-333
Regulatory Considerations for Combined Drug-Device Studies in Europe: A Case Study Involving Bile Sampling
- Open Access
- 20 March 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 43-54
Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling. The IQ Consortium's Human Mass Balance Radiolabeled ADME (hADME) Working Group developed this perspective to address key considerations and highlight opportunities for these studies. This is particularly relevant as regulatory guidance, such as the 2024 US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA), have finalized dedicated guidance documents, along with recommendations from other global regulatory bodies (including European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (of Japan; PMDA)); still, there are some regional differences. This review outlines current practices and emerging trends in hADME study design. It details seven clinical designs, from conventional radiolabeled approaches to microtracer studies that employ analytical techniques, such as accelerator mass spectrometry (AMS). It further highlights alternative non‐radioactive approaches, including the use of Fluorine‐19 nuclear magnetic resonance ( 19 F‐NMR) spectroscopy. The manuscript also explores the integration of hADME studies with absolute bioavailability (ABA) assessments and highlights their impact on early drug development with case studies. This collective effort by the IQ working group highlights fit‐for‐purpose study designs to ensure comprehensive ADME characterization supporting drug registration and patient well‐being.
- 20 March 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 43-54
Open AccessAdvances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling. The IQ Consortium's Human Mass Balance Radiolabeled ADME (hADME) Working Group developed this perspective to address key considerations and highlight opportunities for these studies. This is particularly relevant as regulatory guidance, such as the 2024 US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA), have finalized dedicated guidance documents, along with recommendations from other global regulatory bodies (including European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (of Japan; PMDA)); still, there are some regional differences. This review outlines current practices and emerging trends in hADME study design. It details seven clinical designs, from conventional radiolabeled approaches to microtracer studies that employ analytical techniques, such as accelerator mass spectrometry (AMS). It further highlights alternative non‐radioactive approaches, including the use of Fluorine‐19 nuclear magnetic resonance ( 19 F‐NMR) spectroscopy. The manuscript also explores the integration of hADME studies with absolute bioavailability (ABA) assessments and highlights their impact on early drug development with case studies. This collective effort by the IQ working group highlights fit‐for‐purpose study designs to ensure comprehensive ADME characterization supporting drug registration and patient well‐being.
- Open Access
- 17 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 591-597
Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework
Radiolabeled human mass balance studies are crucial for identifying circulating metabolites and understanding drug absorption, excretion, and clearance pathways. Metabolite profiling involves quantifying all drug‐related entities, including parent drug and metabolites in plasma and excreta, using extended liquid chromatography methods coupled with detection through scintillation counting, accelerator mass spectrometry, or non‐radiolabeled approaches. Given the labor‐intensive nature of sample extraction and analysis, we propose a new paradigm that maximizes gathering information through sample pooling strategies. Our proposal introduces sample pooling strategies by integrating both individual and pooled sample schemes, simplifying decisions, and consolidating existing knowledge into a cohesive document. This aligns with the low statistical power typically associated with mass balance studies that dose six to eight subjects. In metabolite profiling, it is common practice to pool samples either from the limited number of subjects participating in a human mass balance study or from different time points of sample collection. This approach improves efficiency while preserving data integrity. Pooling reduces resource constraints and enables the concentration of samples with relatively low radioactivity levels, resulting in higher quality metabolite profiles. Nevertheless, there are situations when analyzing samples from individual subjects or time points may be preferred. This proposal presents guidance and decision trees designed to facilitate informed decisions about sample pooling to maximize data quality of metabolite profiling in human mass balance studies while efficiently managing resources. These recommendations stem from discussions within the mass balance working group of the IQ Consortium.
- 17 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 591-597
Open AccessGuided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework
Radiolabeled human mass balance studies are crucial for identifying circulating metabolites and understanding drug absorption, excretion, and clearance pathways. Metabolite profiling involves quantifying all drug‐related entities, including parent drug and metabolites in plasma and excreta, using extended liquid chromatography methods coupled with detection through scintillation counting, accelerator mass spectrometry, or non‐radiolabeled approaches. Given the labor‐intensive nature of sample extraction and analysis, we propose a new paradigm that maximizes gathering information through sample pooling strategies. Our proposal introduces sample pooling strategies by integrating both individual and pooled sample schemes, simplifying decisions, and consolidating existing knowledge into a cohesive document. This aligns with the low statistical power typically associated with mass balance studies that dose six to eight subjects. In metabolite profiling, it is common practice to pool samples either from the limited number of subjects participating in a human mass balance study or from different time points of sample collection. This approach improves efficiency while preserving data integrity. Pooling reduces resource constraints and enables the concentration of samples with relatively low radioactivity levels, resulting in higher quality metabolite profiles. Nevertheless, there are situations when analyzing samples from individual subjects or time points may be preferred. This proposal presents guidance and decision trees designed to facilitate informed decisions about sample pooling to maximize data quality of metabolite profiling in human mass balance studies while efficiently managing resources. These recommendations stem from discussions within the mass balance working group of the IQ Consortium.
- Open Access
- 23 January 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (3) , 100041
Cross-industry demonstration of the validity of the mixed matrix method for the assessment of cross-species exposure coverage of human circulating drug metabolites
- 23 January 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (3) , 100041
Open AccessCross-industry demonstration of the validity of the mixed matrix method for the assessment of cross-species exposure coverage of human circulating drug metabolites
- Open Access
- 31 October 2024
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 45 (4) , 677-689
Preclinical in vitro and in vivo evaluation of [ 11 C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates
This paper describes the preclinical validation of the radioligand [ 11 C]ORM-13070 and its tritiated analog for addressing selectivity and occupancy of the selective alpha-2C adrenergic receptor (α 2C R) antagonist BAY 292 in the cynomolgus brain. BAY 292 is a novel drug candidate being developed for the treatment of obstructive sleep apnea (OSA) via binding to central α 2C R. In vitro autoradiography studies with sections from non-diseased post-mortem human caudate revealed an excellent specific binding window (>80%) using [ 3 H]ORM-13070. BAY 292 bound to the same binding site as [ 3 H]ORM-13070 and generated a good specific binding signal, with greater selectivity for α 2C R. In non-human primates in vivo , [ 11 C]ORM-13070 demonstrated a reversible behavior, with uptake at baseline highest in striatum (putamen, caudate, ventral striatum, and pallidum) and low in the cerebellar cortex, consistent with the known distribution of the α 2C R. A dose dependent increase in receptor occupancy after BAY 292 administration was observed, confirming BBB penetration and target engagement. The estimated EC 50 for BAY 292 is 33.39 ± 11.91 ng/mL. This study aimed to demonstrate the suitability of [ 11 C]ORM-13070 as a PET-radioligand for the study of α 2C R in the non-human primate brain, and to pave the way for future clinical PET tracer studies with BAY 292.
- 31 October 2024
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 45 (4) , 677-689
Open AccessPreclinical in vitro and in vivo evaluation of [ 11 C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates
This paper describes the preclinical validation of the radioligand [ 11 C]ORM-13070 and its tritiated analog for addressing selectivity and occupancy of the selective alpha-2C adrenergic receptor (α 2C R) antagonist BAY 292 in the cynomolgus brain. BAY 292 is a novel drug candidate being developed for the treatment of obstructive sleep apnea (OSA) via binding to central α 2C R. In vitro autoradiography studies with sections from non-diseased post-mortem human caudate revealed an excellent specific binding window (>80%) using [ 3 H]ORM-13070. BAY 292 bound to the same binding site as [ 3 H]ORM-13070 and generated a good specific binding signal, with greater selectivity for α 2C R. In non-human primates in vivo , [ 11 C]ORM-13070 demonstrated a reversible behavior, with uptake at baseline highest in striatum (putamen, caudate, ventral striatum, and pallidum) and low in the cerebellar cortex, consistent with the known distribution of the α 2C R. A dose dependent increase in receptor occupancy after BAY 292 administration was observed, confirming BBB penetration and target engagement. The estimated EC 50 for BAY 292 is 33.39 ± 11.91 ng/mL. This study aimed to demonstrate the suitability of [ 11 C]ORM-13070 as a PET-radioligand for the study of α 2C R in the non-human primate brain, and to pave the way for future clinical PET tracer studies with BAY 292.
- Open Access
- 1 March 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 130, 11-20
Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
- 1 March 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 130, 11-20
Open AccessPharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
- Open Access
- 5 December 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 24 (68)
Frontispiece: Enzymatic Late‐Stage Oxidation of Lead Compounds with Solubilizing Biomimetic Docking/Protecting groups
- 5 December 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 24 (68)
Open AccessFrontispiece: Enzymatic Late‐Stage Oxidation of Lead Compounds with Solubilizing Biomimetic Docking/Protecting groups
- 19 November 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 24 (68) , 17936-17947
Enzymatic Late‐Stage Oxidation of Lead Compounds with Solubilizing Biomimetic Docking/Protecting groups
Late‐stage functionalization of lead compounds is of high interest in drug discovery since it offers an easy access to metabolites and derivatives of a lead compound without the need to redesign an often long multistep synthesis. Owing to their high degree of chemoselectivity, biocatalytic transformations, enzymatic oxidations in particular, are potentially very powerful because they could allow the synthesis of less lipophilic derivatives of a lead compound. In the majority of cases, enzymatic oxidations have been used in an empirical way as their regioselectivity is difficult to predict. In this publication, the concept of using docking/protecting groups in a biomimetic fashion was investigated, which could help steer the regioselectivity of a P450BM3‐mediated oxidation. A novel set of docking/protecting groups was designed that can be cleaved under very mild conditions and address the often problematic aqueous solubility of the substrates. Vabicaserin was used as tool compound containing typical groups such as basic, aliphatic, and aromatic moieties. The results were rationalized with the help of in silico docking and molecular dynamic studies.
- 19 November 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 24 (68) , 17936-17947
Enzymatic Late‐Stage Oxidation of Lead Compounds with Solubilizing Biomimetic Docking/Protecting groups
Late‐stage functionalization of lead compounds is of high interest in drug discovery since it offers an easy access to metabolites and derivatives of a lead compound without the need to redesign an often long multistep synthesis. Owing to their high degree of chemoselectivity, biocatalytic transformations, enzymatic oxidations in particular, are potentially very powerful because they could allow the synthesis of less lipophilic derivatives of a lead compound. In the majority of cases, enzymatic oxidations have been used in an empirical way as their regioselectivity is difficult to predict. In this publication, the concept of using docking/protecting groups in a biomimetic fashion was investigated, which could help steer the regioselectivity of a P450BM3‐mediated oxidation. A novel set of docking/protecting groups was designed that can be cleaved under very mild conditions and address the often problematic aqueous solubility of the substrates. Vabicaserin was used as tool compound containing typical groups such as basic, aliphatic, and aromatic moieties. The results were rationalized with the help of in silico docking and molecular dynamic studies.